XML 48 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Supplemental Financial Information
 12 Months Ended
Dec. 31, 2024
Balance Sheet Related Disclosures [Abstract]  
Supplemental Financial Information Supplemental Financial Information
The following tables show the Company’s additional balance sheet information as of December 31, 2024 and 2023:

As of December 31,
20242023
(in thousands)
Inventories:
Raw materials$103 $— 
Work-in-progress— 100 
Finished goods128 281 
Inventory$231 $381 

As of December 31,
20242023
(in thousands)
Accrued Liabilities:
Accrued research and development services$12,251 $3,705 
Accrued compensation and benefits14,712 9,591 
Short term lease liability1,175 1,291 
Other2,309 2,570 
Accrued liabilities$30,447 $17,157 

During the years ended December 31, 2024 and 2022 the Company incurred $1.1 million and $0.3 million, respectively, of severance expense reflected in research and development expenses. During the years ended December 31, 2024
and 2023 the Company incurred $11.2 million and $1.4 million, respectively, of severance expense reflected in selling, general, and administrative expenses. The Company incurred no severance costs in either research and development expenses in 2023 or selling, general, and administrative expenses in 2022. As of December 31, 2024 and 2023, $8.8 million and $0.7 million of severance is reflected as accrued compensation and benefits within accrued liabilities on the consolidated balance sheet as noted in the table above. As of December 31, 2024, $3.7 million of the total 2024 severance expense incurred had been paid. Approximately $7.7 million of the remaining December 31, 2024 accrued severance is expected to be paid by March 31, 2025.